نتایج جستجو برای: rivaroxaban

تعداد نتایج: 2574  

Journal: :Seminars in thrombosis and hemostasis 2007
Volker Laux Elisabeth Perzborn Dagmar Kubitza Frank Misselwitz

There are several novel anticoagulants in development that target factor Xa(FXa)-the pivotal point of the coagulation cascade. One promising agent is rivaroxaban (a highly selective, oral, direct FXa inhibitor), which is in advanced clinical development for the prevention and treatment of thromboembolic disorders. Oral rivaroxaban may be given in fixed once-daily doses, with the potential for n...

Journal: :Thrombosis and haemostasis 2015
P Vranckx F W G Leebeek J G P Tijssen J Koolen F Stammen J-P R Herman R J de Winter A W J van T Hof B Backx W Lindeboom S-Y Kim B Kirsch M van Eickels F Misselwitz F W A Verheugt

Patients on rivaroxaban requiring percutaneous coronary intervention (PCI) represent a clinical conundrum. We aimed to investigate whether rivaroxaban, with or without an additional bolus of unfractionated heparin (UFH), effectively inhibits coagulation activation during PCI. Stable patients (n=108) undergoing elective PCI and on stable dual antiplatelet therapy were randomised (2:2:2:1) to a s...

2018
E. Perzborn D. Kubitza F. Misselwitz

Rivaroxaban (Xarelto®) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. Rivaroxaban inhibits clot-associated and free FXa activity, and prothrombinase activity, and reduces thrombin generation. In animal models, rivaroxaban prevented venous and arterial thrombosis, and was effective at treating venous thro...

Journal: :The New England journal of medicine 2017
John W Eikelboom Stuart J Connolly Jackie Bosch Gilles R Dagenais Robert G Hart Olga Shestakovska Rafael Diaz Marco Alings Eva M Lonn Sonia S Anand Petr Widimsky Masatsugu Hori Alvaro Avezum Leopoldo S Piegas Kelley R H Branch Jeffrey Probstfield Deepak L Bhatt Jun Zhu Yan Liang Aldo P Maggioni Patricio Lopez-Jaramillo Martin O'Donnell Ajay K Kakkar Keith A A Fox Alexander N Parkhomenko Georg Ertl Stefan Störk Matyas Keltai Lars Ryden Nana Pogosova Antonio L Dans Fernando Lanas Patrick J Commerford Christian Torp-Pedersen Tomek J Guzik Peter B Verhamme Dragos Vinereanu Jae-Hyung Kim Andrew M Tonkin Basil S Lewis Camilo Felix Khalid Yusoff P Gabriel Steg Kaj P Metsarinne Nancy Cook Bruns Frank Misselwitz Edmond Chen Darryl Leong Salim Yusuf

BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily)...

2016
Jay M. Margolis Steven Deitelzweig Jeffrey Kline Oth Tran David M. Smith Brahim Bookhart Concetta Crivera Jeff Schein

BACKGROUND Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, results in a substantial healthcare system burden. This retrospective observational study compared hospital length of stay (LOS) and hospitalization costs for patients with venous thromboembolism treated with rivaroxaban versus those treated with warfarin. METHODS AND RESULTS Hospitalizations for adult p...

Journal: :JAMA internal medicine 2014
Evangelia Liakoni Alexandra E Rätz Bravo Luigi Terracciano Markus Heim Stephan Krähenbühl

IMPORTANCE Treatment with the new oral anticoagulant rivaroxaban can be associated with severe liver injury. OBSERVATIONS We report 2 patients with predominantly hepatocellular liver injury that had onset during treatment with rivaroxaban. Both were symptomatic, had massively elevated transaminase activity levels and hyperbilirubinemia, and fulfilled the criteria of Hy's law. Liver biopsy in ...

Journal: :Thrombosis and haemostasis 2018
A John Camm

Rivaroxaban is a non-vitamin K antagonist oral anticoagulant that acts as a direct factor Xa inhibitor, and is widely used for the prevention and treatment of thromboembolic disorders. As further knowledge gaps are identified in thrombosis management, the rivaroxaban research program has expanded in an attempt to elucidate the wider benefits of rivaroxaban. An increased understanding of the int...

Journal: :The Journal of pharmacology and experimental therapeutics 2011
Mark Jean Gnoth Ulf Buetehorn Uwe Muenster Thomas Schwarz Steffen Sandmann

Rivaroxaban, an oral, direct factor Xa inhibitor, has a dual mode of elimination in humans, with two-thirds metabolized by the liver and one-third renally excreted unchanged. P-glycoprotein (P-gp) is known to be involved in the absorption, distribution, and excretion of drugs. To investigate whether rivaroxaban is a substrate of P-gp, the bidirectional flux of rivaroxaban across Caco-2, wild-ty...

Journal: :Croatian medical journal 2010
Vladimir Trkulja Robert Kolundzic

AIM To indirectly compare rivaroxaban and dabigatran for prevention of venous thromboembolism (VTE) after total hip or knee arthroplasty (THA, TKA) based on their pivotal efficacy/safety trials embracing a total of 20618 patients. METHODS Pooled risk differences (RD) for rivaroxaban vs enoxaparin and dabigatran vs enoxaparin obtained from separate meta-analyses of two sets of trials were used...

Journal: :Journal of hepatology 2014
Stefan Russmann David F Niedrig Mathias Budmiger Caroline Schmidt Bruno Stieger Sandra Hürlimann Gerd A Kullak-Ublick

BACKGROUND & AIMS Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders. Although liver injury was observed in premarketing trials of rivaroxaban, there are no published postmarketing cases of liver injury associated with rivaroxaban. METHODS Report of 14 cases of liver i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید